NEW YORK, Feb. 22 - Belgian functional genomics company Devgen on Friday said it has created a complete C. elegans RNA interference library.
The library is genome-wide, including complexes that can suppress the activity of each of the 19,000 C. elegans genes. Devgen plans to use the library in drug-target identification and functional validation.
RNAi is a form of post-transcriptional gene silencing that works by targeting and cleaving endogenous mRNA.
Devgen, based in Ghent, uses C. elegans as a model for target and drug discovery. It uses RNAi knockdown technology in the worm to evaluate gene function, and combines that technique with a comparative-genomics approach to understand human homologues of disease pathways.
The company, which employs about 90 people, is privately held. It has partnerships with Princeton, NJ-based FMC Corp. for new pesticide discovery, and with Metabolex for diabetes research.